Der Vaart Sandra Van Sells 548 Shares of Labcorp (NYSE:LH) Stock

Labcorp Holdings Inc. (NYSE:LH) EVP Der Vaart Sandra Van sold 548 shares of the stock in a transaction on Friday, February 27th. The stock was sold at an average price of $284.91, for a total transaction of $156,130.68. Following the sale, the executive vice president owned 2,579 shares of the company’s stock, valued at approximately $734,782.89. This trade represents a 17.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Labcorp Trading Down 2.4%

LH stock traded down $6.82 during midday trading on Tuesday, hitting $279.65. The stock had a trading volume of 102,507 shares, compared to its average volume of 762,002. The company has a current ratio of 1.42, a quick ratio of 1.23 and a debt-to-equity ratio of 0.60. The firm has a market cap of $23.04 billion, a P/E ratio of 26.74, a price-to-earnings-growth ratio of 1.97 and a beta of 1.01. The business has a fifty day moving average price of $269.13 and a two-hundred day moving average price of $270.10. Labcorp Holdings Inc. has a 1-year low of $209.38 and a 1-year high of $293.72.

Labcorp (NYSE:LH) last posted its quarterly earnings data on Tuesday, February 17th. The medical research company reported $4.07 earnings per share for the quarter, topping the consensus estimate of $3.95 by $0.12. Labcorp had a return on equity of 16.16% and a net margin of 6.28%.The firm had revenue of $3.52 billion during the quarter, compared to analyst estimates of $3.56 billion. During the same period last year, the company posted $3.45 EPS. The business’s quarterly revenue was up 5.6% on a year-over-year basis. Labcorp has set its FY 2026 guidance at 17.550-18.250 EPS. On average, sell-side analysts predict that Labcorp Holdings Inc. will post 16.01 earnings per share for the current fiscal year.

Labcorp Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 12th. Shareholders of record on Friday, February 27th will be issued a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date is Friday, February 27th. Labcorp’s dividend payout ratio (DPR) is presently 27.53%.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on LH. JPMorgan Chase & Co. upped their price target on Labcorp from $319.00 to $330.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 18th. Wall Street Zen raised Labcorp from a “hold” rating to a “buy” rating in a research report on Friday, January 23rd. Piper Sandler lifted their price target on shares of Labcorp from $270.00 to $300.00 and gave the company a “neutral” rating in a research report on Tuesday, February 24th. Morgan Stanley restated an “overweight” rating on shares of Labcorp in a research note on Tuesday, February 17th. Finally, Robert W. Baird raised their price objective on shares of Labcorp from $313.00 to $326.00 and gave the company an “outperform” rating in a research note on Wednesday, February 18th. Ten analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $304.42.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. REAP Financial Group LLC boosted its stake in shares of Labcorp by 20.4% in the 4th quarter. REAP Financial Group LLC now owns 218 shares of the medical research company’s stock worth $55,000 after buying an additional 37 shares during the last quarter. SP Asset Management LLC boosted its position in Labcorp by 0.3% in the second quarter. SP Asset Management LLC now owns 14,177 shares of the medical research company’s stock worth $3,722,000 after purchasing an additional 38 shares during the last quarter. HBK Sorce Advisory LLC grew its stake in Labcorp by 4.3% in the 3rd quarter. HBK Sorce Advisory LLC now owns 916 shares of the medical research company’s stock valued at $254,000 after purchasing an additional 38 shares during the period. Pure Financial Advisors LLC increased its position in shares of Labcorp by 3.9% during the 3rd quarter. Pure Financial Advisors LLC now owns 1,017 shares of the medical research company’s stock valued at $292,000 after purchasing an additional 38 shares during the last quarter. Finally, Zions Bancorporation National Association UT raised its stake in shares of Labcorp by 21.9% during the 2nd quarter. Zions Bancorporation National Association UT now owns 223 shares of the medical research company’s stock worth $59,000 after purchasing an additional 40 shares during the period. 95.94% of the stock is currently owned by hedge funds and other institutional investors.

About Labcorp

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.